The potential therapeutic applications of drugs affecting the ghrelin pathway extend beyond obesity to a variety of disorders including anorexia, gastrointestinal issues, inflammation, substance abuse, cardiovascular, pulmonary, and renal diseases, as well as neurological disorders such as epilepsy, Alzheimer's disease, multiple sclerosis, and Parkinson's disease.92, 93, 94, 95. This evidence concerns the gene GHRL and obesity due to melanocortin 4 receptor deficiency.